Can a new drug combo outperform standard therapy for lung cancer?
NCT ID NCT07756645
First seen Aug 10, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Participants are randomly assigned to one of two treatment groups, and the study measures how long they live without the cancer growing and overall survival. The goal is to see if this new combination can offer a more effective first-line option for this type of lung cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-1480 (an investigational drug) combined with chemotherapy
- What this could lead to
- If ABBV-1480 outperforms pembrolizumab, it could become a new first-line treatment option for advanced squamous non-small cell lung cancer, potentially extending life or delaying cancer growth.
- What could go wrong
- This is an early-phase 3 trial, so results are not guaranteed. The experimental drug may not be more effective than the current standard, and combining it with chemotherapy could increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?